StoneX maintains DexCom at Buy, raises price target to $93 from $82

What happened

StoneX maintained its Buy rating on DexCom and raised its price target to $93 from $82, a 13.4% increase. The new target implies 16.4% upside from DexCom's October 29 close of $79.93.

Confirmed

Global impact / market context

A higher price target signals that StoneX expects DexCom shares to be worth more than previously estimated. For investors, this can support confidence in holding the stock, though it reflects one analyst's view rather than a guaranteed outcome.

Analyst inference

Other recent analyst notes on DexCom show price targets ranging from $96 to $115, above StoneX's $93 target. This suggests StoneX's updated view remains more cautious than some peers even after the increase.

Analyst inference

What to watch

1. StoneX's $93 target sits below the $96 to $115 range from the three most recent analyst notes on DexCom published over the past 30 days. Confirmed
2. Watch whether other analysts change their DexCom price targets or ratings, which would show whether views on the stock are shifting. Proposed
3. DexCom's next financial results could test whether the expected upside materializes, since targets rest on future profit and revenue expectations. Analyst inference

Evidence

• Original source link unavailable